Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
S*Bio logo — Pioneering the future of cancer treatment through innovative...

S*Bio

Pioneering the future of cancer treatment through innovative small molecule drugs.

Founded 2000 Private Equity Total: $143.50M Biotechnology, Pharmaceutical

General Information

Company Name S*Bio
Founded Year 2000
Industries Biotechnology, Pharmaceutical
Funding Stage Private Equity
Social

BounceWatch is an independent company data service, not affiliated with S*Bio. To contact S*Bio, visit sbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About S*Bio

S*Bio is a Singapore-based biotech company founded in 2000 and operating as a subsidiary of Chiron Corporation Limited. Specializing in Biotechnology and Pharmaceutical industries, the company is focused on pioneering the future of cancer treatment through innovative small molecule drugs. The latest investment of $5.00M through a Private Equity Round took place on 23 September 2010 and was made by Mitsui Global Investment. S*BIO Pte, Ltd. has been dedicated to discovering and clinically developing novel targeted small drugs to treat cancer, serving the biotechnology industry in Singapore.

Taxonomy: biotech industry, cancer treatment, drug discovery, small molecule drugs, Singapore-based, clinical development, targeted therapies, oncology, Chiron Corporation Limited, innovation

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round $5.00M 1
Mitsui Global Investment
Mitsui Global Investment
23 Sep 2010
Venture Round $112.50M 1
Adastra Pharmaceuticals
21 Jan 2009
Venture Round $26.00M 6
EDBI 5AM Ventures Aravis
EDBI, 5AM Ventures +4
20 Oct 2008

S*Bio Alternatives & Competitors

View All Alternatives
S*Bio vs
858 Therapeutics
858 Therapeutics United States

Discovering innovative small molecule therapeutics for the treatment of cancer

Venture round
30 employees
Biotechnology, Health Care
S*Bio vs
Advenchen Laboratories, LLC
Advenchen Laboratories, LLC

Pioneering novel therapies with promising small molecule kinase inhibitors for a brighter future in...

Venture round
6 employees
Biotechnology, Health Care
S*Bio vs
Synta Pharmaceuticals
Synta Pharmaceuticals

Innovating patient care with advanced small molecule therapies for severe medical conditions, includ...

Post-IPO Equity
Biotechnology, Health Care
View all alternatives

FAQ About S*Bio

Pioneering the future of cancer treatment through innovative small molecule drugs.
S*Bio was founded in 2000.
S*Bio operates in Biotechnology and Pharmaceutical. Its work centres on biotech industry, cancer treatment, drug discovery and small molecule drugs.
S*Bio has completed 3 funding rounds, raising a total of $143.50M. The latest funding stage is Private Equity.
Top alternatives and competitors to S*Bio include 858 Therapeutics, Advenchen Laboratories, LLC, Synta Pharmaceuticals, ABM Therapeutics, Inthera Bioscience. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
S*Bio and 858 Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for S*Bio, https://bouncewatch.com/company/sbio, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes